The possibility that requiring high-dose olanzapine cannot be explained by pharmacokinetics in the treatment of acute-phase schizophrenia.
Hatta K, Takebayashi H, Sudo Y, Katayama S, Kasuya M, Shirai Y, Morikawa F, Nakase R, Nakamura M, Ito S, Kuga H, Nakamura M, Ohnuma T, Usui C, Nakamura H, Hirata T, Sawa Y; JAST study group.
Hatta K, et al. Among authors: nakamura m, nakamura h.
Psychiatry Res. 2013 Dec 15;210(2):396-401. doi: 10.1016/j.psychres.2013.07.005. Epub 2013 Aug 4.
Psychiatry Res. 2013.
PMID: 23919898
Clinical Trial.